Moderna booster candidate shows strong response against Omicron subvariants
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- Wall St edges up on AI enthusiasm, Mideast negotiation hopes
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices drop about 3% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- S&P 500 ends marginally lower as investors focus on US-Iran war
Cowen Reiterates Market Perform Rating on Moderna (MRNA), 'there is a clear benefit to continued boosting'
June 22, 2022 11:45 AM EDTCowen analyst Tyler Van Buren reiterated a Market Perform rating and $165.00 price target on Moderna (NASDAQ: MRNA).
The analyst comments "Regardless of prior infection status, 1273.214 was noted to elicit potent nAb titers against BA.4 and BA.5. In all participants, 1-month nAb titers increased 5.4-fold over baseline, but were ~3-fold lower than the nAb titers against Omicron (GMT of 941 vs 3000). In baseline... More
Piper Sandler Reiterates Overweight Rating on Moderna (MRNA), PT $214
June 22, 2022 11:17 AM EDTPiper Sandler analyst Edward A. Tenthoff reiterated an Overweight rating and $214.00 price target on Moderna (NASDAQ: MRNA)
The analyst comments "Moderna announced new clinical data on bivalent Omicron booster, mRNA-1273.214. In previously vaccinated and boosted patients, 50µg mRNA-1273.214 induced neutralizing titers against omicron... More
Brookline Capital Markets Maintains $506 PT and Buy Rating on Moderna (MRNA), Annouced Data 'Supports Our Outlook'
June 22, 2022 11:13 AM EDTBrookline Capital Markets analyst Leah Rush Cann reiterated a Buy rating and $506.00 price target on Moderna (NASDAQ: MRNA).
The analyst comments "Highly Positive Phase II/III Data for Bivalent Booster, mRNA-1273-214 - Moderna announced today new clinical data on its bivalent (Omicron) COVID booster candidate, mRNA-1273.214. Data show that one month... More
